88 REFERENCES 1. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 . 2. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60, 277‐ 300 (2010). 3. Boffetta, P. Human cancer from environmental pollutants: the epidemiological evidence. Mutat Res 608, 157‐162 (2006). 4. Vineis, P., et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 330, 277 (2005). 5. Freudenheim, J.L., et al. Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. Am J Clin Nutr 82, 657‐667 (2005). 6. Lee, I.M. Physical activity and cancer prevention‐‐data from epidemiologic studies. Med Sci Sports Exerc 35, 1823‐1827 (2003). 7. Vineis, P. & Husgafvel‐Pursiainen, K. Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 26, 1846‐1855 (2005). 8. Boffetta, P. Epidemiology of environmental and occupational cancer. Oncogene 23, 6392‐6403 (2004). 9. Hwang, S.J., et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113, 238‐243 (2003). 10. Bailey‐Wilson, J.E., et al. A major lung cancer susceptibility locus maps to chromosome 6q23‐25. Am J Hum Genet 75, 460‐474 (2004). 11. Thorgeirsson, T.E., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638‐642 (2008). 12. Hung, R.J., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633‐637 (2008). 13. Amos, C.I., et al. Genome‐wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40, 616‐622 (2008). 14. Sher, T., Dy, G.K. & Adjei, A.A. Small cell lung cancer. Mayo Clin Proc 83, 355‐367 (2008). 15. Otterson, G., Lin, A. & Kay, F. Genetic etiology of lung cancer. Oncology (Williston Park) 6, 97‐104, 107; discussion 108, 111‐102 (1992). 16. Fernandez, F.G. & Battafarano, R.J. Large‐cell neuroendocrine carcinoma of the lung. Cancer Control 13, 270‐275 (2006). 17. Travis, W.D., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22, 934‐944 (1998). 18. Lai, S.L., et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 81, 1144‐1150 (1989). 19. Filosso, P.L., et al. Long‐term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 21, 913‐917 (2002). 20. Charloux, A., et al. International differences in epidemiology of lung adenocarcinoma. Lung Cancer 16, 133‐143 (1997). 21. Charloux, A., et al. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 26, 14‐23 (1997). 22. Travis WD, C.T., Corrin B, Shimosato Y, Brambilla E. World Health Organization International Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours. Vol. 3 (Springer‐Verlag, 1999).
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
88
REFERENCES 1. http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900. 2. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60, 277‐
300 (2010). 3. Boffetta, P. Human cancer from environmental pollutants: the epidemiological
evidence. Mutat Res 608, 157‐162 (2006). 4. Vineis, P., et al. Environmental tobacco smoke and risk of respiratory cancer and chronic
obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 330, 277 (2005).
5. Freudenheim, J.L., et al. Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. Am J Clin Nutr 82, 657‐667 (2005).
6. Lee, I.M. Physical activity and cancer prevention‐‐data from epidemiologic studies. Med Sci Sports Exerc 35, 1823‐1827 (2003).
7. Vineis, P. & Husgafvel‐Pursiainen, K. Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 26, 1846‐1855 (2005).
8. Boffetta, P. Epidemiology of environmental and occupational cancer. Oncogene 23, 6392‐6403 (2004).
9. Hwang, S.J., et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113, 238‐243 (2003).
10. Bailey‐Wilson, J.E., et al. A major lung cancer susceptibility locus maps to chromosome 6q23‐25. Am J Hum Genet 75, 460‐474 (2004).
11. Thorgeirsson, T.E., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638‐642 (2008).
12. Hung, R.J., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633‐637 (2008).
13. Amos, C.I., et al. Genome‐wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40, 616‐622 (2008).
14. Sher, T., Dy, G.K. & Adjei, A.A. Small cell lung cancer. Mayo Clin Proc 83, 355‐367 (2008). 15. Otterson, G., Lin, A. & Kay, F. Genetic etiology of lung cancer. Oncology (Williston Park)
6, 97‐104, 107; discussion 108, 111‐102 (1992). 16. Fernandez, F.G. & Battafarano, R.J. Large‐cell neuroendocrine carcinoma of the lung.
Cancer Control 13, 270‐275 (2006). 17. Travis, W.D., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with
clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22, 934‐944 (1998).
18. Lai, S.L., et al. MDR1 gene expression in lung cancer. J Natl Cancer Inst 81, 1144‐1150 (1989).
19. Filosso, P.L., et al. Long‐term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg 21, 913‐917 (2002).
20. Charloux, A., et al. International differences in epidemiology of lung adenocarcinoma. Lung Cancer 16, 133‐143 (1997).
21. Charloux, A., et al. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 26, 14‐23 (1997).
22. Travis WD, C.T., Corrin B, Shimosato Y, Brambilla E. World Health Organization International Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours. Vol. 3 (Springer‐Verlag, 1999).
89
23. William M. Thurlbeck, A.M.C. Pathology of the Lung. (1995). 24. Zhang, H. & Cai, B. The impact of tobacco on lung health in China. Respirology 8, 17‐21
(2003). 25. Arita, T., et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph
nodes. Thorax 50, 1267‐1269 (1995). 26. Marom, E.M., et al. Staging non‐small cell lung cancer with whole‐body PET. Radiology
212, 803‐809 (1999). 27. Weder, W., et al. Detection of extrathoracic metastases by positron emission
tomography in lung cancer. Ann Thorac Surg 66, 886‐892; discussion 892‐883 (1998). 28. Eloubeidi, M.A., et al. Endoscopic ultrasound‐guided fine needle aspiration of
mediastinal lymph node in patients with suspected lung cancer after positron emission tomography and computed tomography scans. Ann Thorac Surg 79, 263‐268 (2005).
29. Kim, K., et al. Combined bronchoscopy, mediastinoscopy, and thoracotomy for lung cancer: who benefits? J Thorac Cardiovasc Surg 127, 850‐856 (2004).
30. Smith, R.A., et al. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001‐‐testing for early lung cancer detection. CA Cancer J Clin 51, 38‐75; quiz 77‐80 (2001).
32. Pfister, D.G., et al. American Society of Clinical Oncology treatment of unresectable non‐small‐cell lung cancer guideline: update 2003. J Clin Oncol 22, 330‐353 (2004).
33. Arriagada, R., et al. Cisplatin‐based adjuvant chemotherapy in patients with completely resected non‐small‐cell lung cancer. N Engl J Med 350, 351‐360 (2004).
34. Winton, T., et al. Vinorelbine plus cisplatin vs. observation in resected non‐small‐cell lung cancer. N Engl J Med 352, 2589‐2597 (2005).
35. Douillard, J.Y., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB‐IIIA non‐small‐cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7, 719‐727 (2006).
36. Strauss, G.M., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non‐small‐cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26, 5043‐5051 (2008).
37. Xu, G., Rong, T. & Lin, P. Adjuvant chemotherapy following radical surgery for non‐small‐cell lung cancer: a randomized study on 70 patients. Chin Med J (Engl) 113, 617‐620 (2000).
38. Mineo, T.C., Ambrogi, V., Corsaro, V. & Roselli, M. Postoperative adjuvant therapy for stage IB non‐small‐cell lung cancer. Eur J Cardiothorac Surg 20, 378‐384 (2001).
39. Nakagawa, K., et al. Randomised study of adjuvant chemotherapy for completely resected p‐stage I‐IIIA non‐small cell lung cancer. Br J Cancer 95, 817‐821 (2006).
40. Imaizumi, M. Postoperative adjuvant cisplatin, vindesine, plus uracil‐tegafur chemotherapy increased survival of patients with completely resected p‐stage I non‐small cell lung cancer. Lung Cancer 49, 85‐94 (2005).
41. Mok, T.S., et al. Gefitinib or carboplatin‐paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947‐957 (2009).
90
42. Mitsudomi, T., et al. Gefitinib versus cisplatin plus docetaxel in patients with non‐small‐cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11, 121‐128 (2010).
43. Maemondo, M., et al. Gefitinib or chemotherapy for non‐small‐cell lung cancer with mutated EGFR. N Engl J Med 362, 2380‐2388 (2010).
44. Giaccone, G., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non‐small‐cell lung cancer: a phase III trial‐‐INTACT 1. J Clin Oncol 22, 777‐784 (2004).
45. Herbst, R.S., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non‐small‐cell lung cancer: a phase III trial‐‐INTACT 2. J Clin Oncol 22, 785‐794 (2004).
46. Herbst, R.S., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI‐774) combined with carboplatin and paclitaxel chemotherapy in advanced non‐small‐cell lung cancer. J Clin Oncol 23, 5892‐5899 (2005).
47. Gatzemeier, U., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non‐small‐cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25, 1545‐1552 (2007).
48. Kelly, K., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non‐small‐cell lung cancer: SWOG S0023. J Clin Oncol 26, 2450‐2456 (2008).
49. Takeda, K., et al. Randomized phase III trial of platinum‐doublet chemotherapy followed by gefitinib compared with continued platinum‐doublet chemotherapy in Japanese patients with advanced non‐small‐cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 28, 753‐760 (2010).
50. Cappuzzo, F., et al. Erlotinib as maintenance treatment in advanced non‐small‐cell lung cancer: a multicentre, randomised, placebo‐controlled phase 3 study. Lancet Oncol 11, 521‐529 (2010).
51. Miller VA, O.C.P., Soh C, Kabbinavar F. A randomized, double‐blind, placebo‐controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first‐line treatment of locally advanced, recurrent, or metastatic non‐small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 27, LBA8002 (2009).
52. Kelsey, C.R., et al. Local recurrence after surgery for early stage lung cancer: an 11‐year experience with 975 patients. Cancer 115, 5218‐5227 (2009).
53. Saynak, M., Higginson, D.S., Morris, D.E. & Marks, L.B. Current status of postoperative radiation for non‐small‐cell lung cancer. Semin Radiat Oncol 20, 192‐200 (2010).
54. Sandler, A.B., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first‐line advanced, unresectable non‐small‐cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27, 1405‐1412 (2009).
55. Stein, R.A. & Staros, J.V. Evolutionary analysis of the ErbB receptor and ligand families. J Mol Evol 50, 397‐412 (2000).
56. Yarden, Y. & Sliwkowski, M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127‐137 (2001).
57. Citri, A., Skaria, K.B. & Yarden, Y. The deaf and the dumb: the biology of ErbB‐2 and ErbB‐3. Exp Cell Res 284, 54‐65 (2003).
58. van der Geer, P., Hunter, T. & Lindberg, R.A. Receptor protein‐tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10, 251‐337 (1994).
59. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211‐225 (2000).
91
60. Schlessinger, J. Ligand‐induced, receptor‐mediated dimerization and activation of EGF receptor. Cell 110, 669‐672 (2002).
61. Lemmon, M.A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117‐1134 (2010).
62. Waterfield, M. Cracking the mild, difficult and fiendish codes within and downstream of the EGFR to link diagnostics and therapeutics. Biochem Soc Trans 35, 1‐6 (2007).
63. Citri, A. & Yarden, Y. EGF‐ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7, 505‐516 (2006).
64. Ferguson, K.M. Structure‐based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37, 353‐373 (2008).
65. Pao, W., Miller, V.A. & Kris, M.G. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non‐small cell lung cancer (NSCLC). Semin Cancer Biol 14, 33‐40 (2004).
66. Wakeling, A.E., et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62, 5749‐5754 (2002).
67. Pollack, V.A., et al. Inhibition of epidermal growth factor receptor‐associated tyrosine phosphorylation in human carcinomas with CP‐358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291, 739‐748 (1999).
68. Perez‐Soler, R., et al. Determinants of tumor response and survival with erlotinib in patients with non‐‐small‐cell lung cancer. J Clin Oncol 22, 3238‐3247 (2004).
69. Hidalgo, M., et al. Phase I and pharmacologic study of OSI‐774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19, 3267‐3279 (2001).
70. Giaccone, G., et al. Erlotinib for frontline treatment of advanced non‐small cell lung cancer: a phase II study. Clin Cancer Res 12, 6049‐6055 (2006).
71. Jackman, D.M., et al. Phase II clinical trial of chemotherapy‐naive patients > or = 70 years of age treated with erlotinib for advanced non‐small‐cell lung cancer. J Clin Oncol 25, 760‐766 (2007).
72. Gridelli, C., et al. Erlotinib in non‐small cell lung cancer treatment: current status and future development. Oncologist 12, 840‐849 (2007).
73. Massarelli, E., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non‐small‐cell lung cancer. Lung Cancer 39, 55‐61 (2003).
74. Shepherd, F.A., et al. Erlotinib in previously treated non‐small‐cell lung cancer. N Engl J Med 353, 123‐132 (2005).
75. Arteaga, C.L. ErbB‐targeted therapeutic approaches in human cancer. Exp Cell Res 284, 122‐130 (2003).
76. Luetteke, N.C., et al. The mouse waved‐2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev 8, 399‐413 (1994).
77. Lynch, T.J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non‐small‐cell lung cancer to gefitinib. N Engl J Med 350, 2129‐2139 (2004).
78. Paez, J.G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497‐1500 (2004).
79. Sahoo, R., et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer (2011).
80. Lopez, M.F., et al. High‐throughput profiling of the mitochondrial proteome using affinity fractionation and automation. Electrophoresis 21, 3427‐3440 (2000).
92
81. Hu, W., Wu, W., Kobayashi, R. & Kavanagh, J.J. Proteomics in cancer screening and management in gynecologic cancer. Curr Oncol Rep 6, 456‐462 (2004).
82. Bichsel, V.E., Liotta, L.A. & Petricoin, E.F., 3rd. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 7, 69‐78 (2001).
83. Walter, G., Bussow, K., Lueking, A. & Glokler, J. High‐throughput protein arrays: prospects for molecular diagnostics. Trends Mol Med 8, 250‐253 (2002).
84. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y.Y. & Chan, D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48, 1296‐1304 (2002).
85. Tangrea, M.A., et al. Expression microdissection: operator‐independent retrieval of cells for molecular profiling. Diagn Mol Pathol 13, 207‐212 (2004).
86. Alaoui‐Jamali, M.A., Dupre, I. & Qiang, H. Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resist Updat 7, 245‐255 (2004).
87. Kopf, E. & Zharhary, D. Antibody arrays‐‐an emerging tool in cancer proteomics. Int J Biochem Cell Biol 39, 1305‐1317 (2007).
88. Hudelist, G., et al. Use of high‐throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res Treat 86, 281‐291 (2004).
89. Misek, D.E., Imafuku, Y. & Hanash, S.M. Application of proteomic technologies to tumor analysis. Pharmacogenomics 5, 1129‐1137 (2004).
90. Sjoholt, G., et al. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Curr Drug Targets 6, 631‐646 (2005).
91. Rajapakse, J.C., Duan, K.B. & Yeo, W.K. Proteomic cancer classification with mass spectrometry data. Am J Pharmacogenomics 5, 281‐292 (2005).
92. Stewart, J.J., et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 5, 433‐443 (2006).
93. Amanchy, R., Kalume, D.E., Iwahori, A., Zhong, J. & Pandey, A. Phosphoproteome analysis of HeLa cells using stable isotope labeling with amino acids in cell culture (SILAC). J Proteome Res 4, 1661‐1671 (2005).
94. Amanchy, R., Kalume, D.E. & Pandey, A. Stable isotope labeling with amino acids in cell culture (SILAC) for studying dynamics of protein abundance and posttranslational modifications. Sci STKE 2005, pl2 (2005).
95. Guha, U., et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer‐specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A 105, 14112‐14117 (2008).
96. Kristiansen, T.Z., Harsha, H.C., Gronborg, M., Maitra, A. & Pandey, A. Differential membrane proteomics using 18O‐labeling to identify biomarkers for cholangiocarcinoma. J Proteome Res 7, 4670‐4677 (2008).
97. Ong, S.E., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1, 376‐386 (2002).
98. Taylor, B.S., Varambally, S. & Chinnaiyan, A.M. A systems approach to model metastatic progression. Cancer Res 66, 5537‐5539 (2006).
93
99. Denkert, C., et al. Mass spectrometry‐based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 66, 10795‐10804 (2006).
100. Harsha, H.C., et al. Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 7, 4651‐4658 (2008).
101. Harsha, H.C., et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 6, e1000046 (2009).
102. Harsha, H.C., Molina, H. & Pandey, A. Quantitative proteomics using stable isotope labeling with amino acids in cell culture. Nat Protoc 3, 505‐516 (2008).
103. Ranganathan, P., Harsha, H.C. & Pandey, A. Molecular alterations in exocrine neoplasms of the pancreas. Arch Pathol Lab Med 133, 405‐412 (2009).
104. Agyeman, A.S., et al. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane‐treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat (2011).
105. Amanchy, R., et al. Identification of c‐Src tyrosine kinase substrates in platelet‐derived growth factor receptor signaling. Mol Oncol 3, 439‐450 (2009).
106. Bose, R., et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A 103, 9773‐9778 (2006).
107. Chaerkady, R. & Pandey, A. Quantitative proteomics for identification of cancer biomarkers. Proteomics Clin Appl 1, 1080‐1089 (2007).
108. Chen, H., et al. Proteomic characterization of Her2/neu‐overexpressing breast cancer cells. Proteomics 10, 3800‐3810 (2010).
109. Gronborg, M., et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5, 157‐171 (2006).
110. Zhong, J., Molina, H. & Pandey, A. Phosphoproteomics. Curr Protoc Protein Sci Chapter 24, Unit 24 24 (2007).
111. Kandasamy, K., Pandey, A. & Molina, H. Evaluation of several MS/MS search algorithms for analysis of spectra derived from electron transfer dissociation experiments. Anal Chem 81, 7170‐7180 (2009).
112. Kim, M.S., Zhong, J., Kandasamy, K., Delanghe, B. & Pandey, A. Systematic evaluation of alternating CID and ETD fragmentation for phosphorylated peptides. Proteomics 11, 2568‐2572 (2011).
113. Molina, H., Horn, D.M., Tang, N., Mathivanan, S. & Pandey, A. Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc Natl Acad Sci U S A 104, 2199‐2204 (2007).
114. Molina, H., Matthiesen, R., Kandasamy, K. & Pandey, A. Comprehensive comparison of collision induced dissociation and electron transfer dissociation. Anal Chem 80, 4825‐4835 (2008).
115. Fujii, K., et al. Clinical‐scale high‐throughput human plasma proteome analysis: lung adenocarcinoma. Proteomics 5, 1150‐1159 (2005).
116. Guergova‐Kuras, M., et al. Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics (2011).
117. Taguchi, A., et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20, 289‐299 (2011).
118. Sudhir, P.R., et al. Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas. PLoS One 6, e20199 (2011).
119. Rahman, S.M., et al. Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res 71, 3009‐3017 (2011).
94
120. Machida, K., Mayer, B.J. & Nollau, P. Profiling the global tyrosine phosphorylation state. Mol Cell Proteomics 2, 215‐233 (2003).
121. Lim, Y.P. Mining the tumor phosphoproteome for cancer markers. Clin Cancer Res 11, 3163‐3169 (2005).
122. Lee, K.B. & Pi, K.B. [Comparative proteomic analysis of cancerous and adjacent normal lung tissues]. Biomed Khim 56, 663‐673 (2010).
123. Watowich, S.S., et al. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol 12, 91‐128 (1996).
124. Fadden, P. & Haystead, T.A. Quantitative and selective fluorophore labeling of phosphoserine on peptides and proteins: characterization at the attomole level by capillary electrophoresis and laser‐induced fluorescence. Anal Biochem 225, 81‐88 (1995).
125. Mann, M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 7, 952‐958 (2006).
126. Gruhler, S. & Kratchmarova, I. Stable isotope labeling by amino acids in cell culture (SILAC). Methods Mol Biol 424, 101‐111 (2008).
127. Emadali, A. & Gallagher‐Gambarelli, M. [Quantitative proteomics by SILAC: practicalities and perspectives for an evolving approach]. Med Sci (Paris) 25, 835‐842 (2009).
128. von Haller, P.D., et al. The application of new software tools to quantitative protein profiling via isotope‐coded affinity tag (ICAT) and tandem mass spectrometry: II. Evaluation of tandem mass spectrometry methodologies for large‐scale protein analysis, and the application of statistical tools for data analysis and interpretation. Mol Cell Proteomics 2, 428‐442 (2003).
129. Everley, P.A., Krijgsveld, J., Zetter, B.R. & Gygi, S.P. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics 3, 729‐735 (2004).
130. Ong, S.E., Mittler, G. & Mann, M. Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. Nat Methods 1, 119‐126 (2004).
131. Pimienta, G., Chaerkady, R. & Pandey, A. SILAC for global phosphoproteomic analysis. Methods Mol Biol 527, 107‐116, x (2009).
132. Cuomo, A. & Bonaldi, T. Systems biology "on‐the‐fly": SILAC‐based quantitative proteomics and RNAi approach in Drosophila melanogaster. Methods Mol Biol 662, 59‐78 (2010).
133. Yang, Y., et al. Identifying targets of miR‐143 using a SILAC‐based proteomic approach. Mol Biosyst 6, 1873‐1882 (2010).
134. de Godoy, L.M., et al. Status of complete proteome analysis by mass spectrometry: SILAC labeled yeast as a model system. Genome Biol 7, R50 (2006).
135. Dilworth, D.J., et al. QTIPS: a novel method of unsupervised determination of isotopic amino acid distribution in SILAC experiments. J Am Soc Mass Spectrom 21, 1417‐1422 (2010).
136. Kruger, M., et al. SILAC mouse for quantitative proteomics uncovers kindlin‐3 as an essential factor for red blood cell function. Cell 134, 353‐364 (2008).
137. Sury, M.D., Chen, J.X. & Selbach, M. The SILAC fly allows for accurate protein quantification in vivo. Mol Cell Proteomics 9, 2173‐2183 (2010).
138. Hanke, S., Besir, H., Oesterhelt, D. & Mann, M. Absolute SILAC for accurate quantitation of proteins in complex mixtures down to the attomole level. J Proteome Res 7, 1118‐1130 (2008).
95
139. Doherty, M.K., Hammond, D.E., Clague, M.J., Gaskell, S.J. & Beynon, R.J. Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J Proteome Res 8, 104‐112 (2009).
140. Schwanhausser, B., Gossen, M., Dittmar, G. & Selbach, M. Global analysis of cellular protein translation by pulsed SILAC. Proteomics 9, 205‐209 (2009).
141. Schuchardt, S. & Borlak, J. Quantitative mass spectrometry to investigate epidermal growth factor receptor phosphorylation dynamics. Mass Spectrom Rev 27, 51‐65 (2008).
142. Moro, L., et al. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion‐dependent cell survival. EMBO J 17, 6622‐6632 (1998).
143. Guo, L., et al. Studies of ligand‐induced site‐specific phosphorylation of epidermal growth factor receptor. J Am Soc Mass Spectrom 14, 1022‐1031 (2003).
144. Olsen, J.V., et al. Global, in vivo, and site‐specific phosphorylation dynamics in signaling networks. Cell 127, 635‐648 (2006).
145. Harris, D.L. & Joyce, N.C. Protein tyrosine phosphatase, PTP1B, expression and activity in rat corneal endothelial cells. Mol Vis 13, 785‐796 (2007).
146. Lombardo, C.R., Consler, T.G. & Kassel, D.B. In vitro phosphorylation of the epidermal growth factor receptor autophosphorylation domain by c‐src: identification of phosphorylation sites and c‐src SH2 domain binding sites. Biochemistry 34, 16456‐16466 (1995).
147. Chattopadhyay, A., Vecchi, M., Ji, Q., Mernaugh, R. & Carpenter, G. The role of individual SH2 domains in mediating association of phospholipase C‐gamma1 with the activated EGF receptor. J Biol Chem 274, 26091‐26097 (1999).
148. Carpenter, G. The EGF receptor: a nexus for trafficking and signaling. Bioessays 22, 697‐707 (2000).
149. Yudushkin, I.A., et al. Live‐cell imaging of enzyme‐substrate interaction reveals spatial regulation of PTP1B. Science 315, 115‐119 (2007).
150. Blagoev, B., et al. A proteomics strategy to elucidate functional protein‐protein interactions applied to EGF signaling. Nat Biotechnol 21, 315‐318 (2003).
151. Schulze, W.X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB‐receptor kinase family. Mol Syst Biol 1, 2005 0008 (2005).
152. Pandey, A., et al. Cloning of a novel phosphotyrosine binding domain containing molecule, Odin, involved in signaling by receptor tyrosine kinases. Oncogene 21, 8029‐8036 (2002).
153. Kratchmarova, I., Blagoev, B., Haack‐Sorensen, M., Kassem, M. & Mann, M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 308, 1472‐1477 (2005).
154. Ibarrola, N., Kalume, D.E., Gronborg, M., Iwahori, A. & Pandey, A. A proteomic approach for quantitation of phosphorylation using stable isotope labeling in cell culture. Anal Chem 75, 6043‐6049 (2003).
155. Mertins, P., et al. Investigation of protein‐tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763‐1777 (2008).
156. Blagoev, B., Ong, S.E., Kratchmarova, I. & Mann, M. Temporal analysis of phosphotyrosine‐dependent signaling networks by quantitative proteomics. Nat Biotechnol 22, 1139‐1145 (2004).
157. Zhang, Y., et al. Time‐resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 4, 1240‐1250 (2005).
96
158. Rikova, K., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190‐1203 (2007).
159. Rush, J., et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 23, 94‐101 (2005).
160. Fujishita, T., et al. Sensitivity of non‐small‐cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel. Oncology 64, 399‐406 (2003).
161. Tracy, S., et al. Gefitinib induces apoptosis in the EGFRL858R non‐small‐cell lung cancer cell line H3255. Cancer Res 64, 7241‐7244 (2004).
162. Engelman, J.A., et al. ErbB‐3 mediates phosphoinositide 3‐kinase activity in gefitinib‐sensitive non‐small cell lung cancer cell lines. Proc Natl Acad Sci U S A 102, 3788‐3793 (2005).
164. Gadgeel, S.M., et al. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase‐2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 110, 2775‐2784 (2007).
165. Taouatas, N., et al. Strong cation exchange‐based fractionation of Lys‐N‐generated peptides facilitates the targeted analysis of post‐translational modifications. Mol Cell Proteomics 8, 190‐200 (2009).
166. Pinkse, M.W., Lemeer, S. & Heck, A.J. A protocol on the use of titanium dioxide chromatography for phosphoproteomics. Methods Mol Biol 753, 215‐228 (2011).
167. Cox, J., et al. A practical guide to the MaxQuant computational platform for SILAC‐based quantitative proteomics. Nat Protoc 4, 698‐705 (2009).
168. Cox, J., et al. Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment. J Proteome Res 10, 1794‐1805 (2011).
169. Hunter, T. A thousand and one protein kinases. Cell 50, 823‐829 (1987). 170. Mustelin, T., Abraham, R.T., Rudd, C.E., Alonso, A. & Merlo, J.J. Protein tyrosine
phosphorylation in T cell signaling. Front Biosci 7, d918‐969 (2002). 171. Mustelin, T., et al. Protein tyrosine phosphatases. Front Biosci 7, d85‐142 (2002). 172. Hunter, T. Signaling‐‐2000 and beyond. Cell 100, 113‐127 (2000). 173. Pawson, T. & Nash, P. Assembly of cell regulatory systems through protein interaction
domains. Science 300, 445‐452 (2003). 174. Hunter, T. & Sefton, B.M. Transforming gene product of Rous sarcoma virus
phosphorylates tyrosine. Proc Natl Acad Sci U S A 77, 1311‐1315 (1980). 175. Engelman, J.A. & Cantley, L.C. The role of the ErbB family members in non‐small cell lung
cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 12, 4372s‐4376s (2006).
176. Wangpaichitr, M., et al. Inhibition of mTOR restores cisplatin sensitivity through down‐regulation of growth and anti‐apoptotic proteins. Eur J Pharmacol 591, 124‐127 (2008).
177. Restuccia, D.F. & Hemmings, B.A. From man to mouse and back again: advances in defining tumor AKTivities in vivo. Dis Model Mech 3, 705‐720 (2010).
178. Guertin, D.A. & Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell 12, 9‐22 (2007).
179. Gomez‐Martin, C., Rubio‐Viqueira, B. & Hidalgo, M. Current status of mammalian target of rapamycin inhibitors in lung cancer. Clin Lung Cancer 7 Suppl 1, S13‐18 (2005).
97
180. Byfield, M.P., Murray, J.T. & Backer, J.M. hVps34 is a nutrient‐regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 280, 33076‐33082 (2005).
181. Sonenberg, N. & Hinnebusch, A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731‐745 (2009).
182. Ruvinsky, I. & Meyuhas, O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31, 342‐348 (2006).
183. Raught, B. & Gingras, A.C. eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 31, 43‐57 (1999).
184. Raught, B., et al. Serum‐stimulated, rapamycin‐sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 19, 434‐444 (2000).
185. Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13, 9‐22 (1999).
186. Joukov, V., et al. A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. EMBO J 15, 290‐298 (1996).
187. Yuan, A., et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non‐small‐cell lung cancer. J Clin Oncol 19, 432‐441 (2001).
188. Fontanini, G., et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non‐small cell lung carcinoma. Clin Cancer Res 3, 861‐865 (1997).
189. Ferrara, N., Gerber, H.P. & LeCouter, J. The biology of VEGF and its receptors. Nat Med 9, 669‐676 (2003).
190. Rocha‐Lima, C.M., Soares, H.P., Raez, L.E. & Singal, R. EGFR targeting of solid tumors. Cancer Control 14, 295‐304 (2007).
191. Pennell, N.A. & Lynch, T.J., Jr. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 14, 399‐411 (2009).
192. Landgren, E., Blume‐Jensen, P., Courtneidge, S.A. & Claesson‐Welsh, L. Fibroblast growth factor receptor‐1 regulation of Src family kinases. Oncogene 10, 2027‐2035 (1995).
193. Volm, M., Koomagi, R., Mattern, J. & Stammler, G. Prognostic value of basic fibroblast growth factor and its receptor (FGFR‐1) in patients with non‐small cell lung carcinomas. Eur J Cancer 33, 691‐693 (1997).
194. Takanami, I., et al. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Eur J Cancer 32A, 1504‐1509 (1996).
195. Slodkowska, J., Sikora, J., Roszkowski‐Sliz, K., Radomyski, A. & Androsiuk, W. Expression of vascular endothelial growth factor and basic fibroblast growth factor receptors in lung cancer. Anal Quant Cytol Histol 22, 398‐402 (2000).
196. Dey, J.H., et al. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 70, 4151‐4162 (2010).
197. Semrad, T.J. & Mack, P.C. Fibroblast Growth Factor Signaling in Non‐Small Cell Lung Cancer. Clin Lung Cancer (2011).
198. Himanen, J.P. & Nikolov, D.B. Eph receptors and ephrins. Int J Biochem Cell Biol 35, 130‐134 (2003).
98
199. Tang, X.X., Brodeur, G.M., Campling, B.G. & Ikegaki, N. Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin‐B ligands in human small cell lung carcinoma. Clin Cancer Res 5, 455‐460 (1999).
200. Hafner, C., et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50, 490‐499 (2004).
201. Yu, J., et al. The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma. Int J Oncol 35, 175‐179 (2009).
202. Sos, M.L., et al. Predicting drug susceptibility of non‐small cell lung cancers based on genetic lesions. J Clin Invest 119, 1727‐1740 (2009).
203. Ding, L., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069‐1075 (2008).
204. Nakamoto, M. & Bergemann, A.D. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59, 58‐67 (2002).
205. Foo, S.S., et al. Ephrin‐B2 controls cell motility and adhesion during blood‐vessel‐wall assembly. Cell 124, 161‐173 (2006).
206. Ogawa, K., et al. The ephrin‐A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19, 6043‐6052 (2000).
207. Stahl, S., et al. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro‐survival signaling through Akt1‐mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566‐2578 (2011).
208. Nasarre, P., Potiron, V., Drabkin, H. & Roche, J. Guidance molecules in lung cancer. Cell Adh Migr 4, 130‐145 (2010).
209. Liu, D., et al. Down‐regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway. J Cancer Res Clin Oncol 137, 1629‐1640 (2011).
210. Song, L., Rawal, B., Nemeth, J.A. & Haura, E.B. JAK1 activates STAT3 activity in non‐small‐cell lung cancer cells and IL‐6 neutralizing antibodies can suppress JAK1‐STAT3 signaling. Mol Cancer Ther 10, 481‐494 (2011).
212. Andersen, J.N., et al. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J 18, 8‐30 (2004).
213. Alonso, A., et al. Protein tyrosine phosphatases in the human genome. Cell 117, 699‐711 (2004).
214. Gandhi, T.K., et al. Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat Genet 38, 285‐293 (2006).
215. Ostman, A., Hellberg, C. & Bohmer, F.D. Protein‐tyrosine phosphatases and cancer. Nat Rev Cancer 6, 307‐320 (2006).
216. Easty, D., Gallagher, W. & Bennett, D.C. Protein tyrosine phosphatases, new targets for cancer therapy. Curr Cancer Drug Targets 6, 519‐532 (2006).
217. Jallal, B., Schlessinger, J. & Ullrich, A. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu‐overexpressing human tumor cells. J Biol Chem 267, 4357‐4363 (1992).
218. Ikuta, S., et al. Expression of cytoskeletal‐associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma. J Gastroenterol 29, 727‐732 (1994).
219. Warabi, M., Nemoto, T., Ohashi, K., Kitagawa, M. & Hirokawa, K. Expression of protein tyrosine phosphatases and its significance in esophageal cancer. Exp Mol Pathol 68, 187‐195 (2000).
99
220. Wu, C.W., et al. PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma. Anticancer Res 26, 1643‐1649 (2006).
221. Hou, S.W., et al. PTPH1 dephosphorylates and cooperates with p38gamma MAPK to increase ras oncogenesis through PDZ‐mediated interaction. Cancer Res 70, 2901‐2910 (2010).
222. De Leon, G., Sherry, T.C. & Krucher, N.A. Reduced expression of PNUTS leads to activation of Rb‐phosphatase and caspase‐mediated apoptosis. Cancer Biol Ther 7, 833‐841 (2008).
223. Grana, X. Downregulation of the phosphatase nuclear targeting subunit (PNUTS) triggers pRB dephosphorylation and apoptosis in pRB positive tumor cell lines. Cancer Biol Ther 7, 842‐844 (2008).
224. den Hertog, J., Tracy, S. & Hunter, T. Phosphorylation of receptor protein‐tyrosine phosphatase alpha on Tyr789, a binding site for the SH3‐SH2‐SH3 adaptor protein GRB‐2 in vivo. EMBO J 13, 3020‐3032 (1994).
225. Su, J., Batzer, A. & Sap, J. Receptor tyrosine phosphatase R‐PTP‐alpha is tyrosine‐phosphorylated and associated with the adaptor protein Grb2. J Biol Chem 269, 18731‐18734 (1994).
226. Su, J., Yang, L.T. & Sap, J. Association between receptor protein‐tyrosine phosphatase RPTPalpha and the Grb2 adaptor. Dual Src homology (SH) 2/SH3 domain requirement and functional consequences. J Biol Chem 271, 28086‐28096 (1996).
227. Ertmer, A., et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 21, 936‐942 (2007).
228. Schmid, K., et al. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer 103, 622‐628 (2010).
229. Blancquaert, S., et al. cAMP‐dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. Mol Endocrinol 24, 1453‐1468 (2010).
230. Armour, S.M., et al. Inhibition of mammalian S6 kinase by resveratrol suppresses autophagy. Aging (Albany NY) 1, 515‐528 (2009).
231. Behrends, C., Sowa, M.E., Gygi, S.P. & Harper, J.W. Network organization of the human autophagy system. Nature 466, 68‐76 (2010).
232. Kirkin, V., McEwan, D.G., Novak, I. & Dikic, I. A role for ubiquitin in selective autophagy. Mol Cell 34, 259‐269 (2009).
233. Mizushima, N. The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 22, 132‐139 (2010).
235. Belham, C., et al. A mitotic cascade of NIMA family kinases. Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem 278, 34897‐34909 (2003).
236. Chen, Y. & Klionsky, D.J. The regulation of autophagy ‐ unanswered questions. J Cell Sci 124, 161‐170 (2011).
237. Ling, Y.H., Lin, R. & Perez‐Soler, R. Erlotinib induces mitochondrial‐mediated apoptosis in human H3255 non‐small‐cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation‐dependent activation of BAX and BAK. Mol Pharmacol 74, 793‐806 (2008).
238. Fimia, G.M. & Piacentini, M. Regulation of autophagy in mammals and its interplay with apoptosis. Cell Mol Life Sci 67, 1581‐1588 (2010).
100
239. Kim, Y.Y., et al. Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense. Cancer Res 69, 8455‐8462 (2009).
240. Kantidakis, T., Ramsbottom, B.A., Birch, J.L., Dowding, S.N. & White, R.J. mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1. Proc Natl Acad Sci U S A 107, 11823‐11828 (2010).
241. Staber, P.B., et al. The oncoprotein NPM‐ALK of anaplastic large‐cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 110, 3374‐3383 (2007).
242. Farras, R., et al. JunB breakdown in mid‐/late G2 is required for down‐regulation of cyclin A2 levels and proper mitosis. Mol Cell Biol 28, 4173‐4187 (2008).
243. Wu, T.T. & Castle, J.D. Tyrosine phosphorylation of selected secretory carrier membrane proteins, SCAMP1 and SCAMP3, and association with the EGF receptor. Mol Biol Cell 9, 1661‐1674 (1998).
244. Ohno, H., et al. Localization of p0071‐interacting proteins, plakophilin‐related armadillo‐repeat protein‐interacting protein (PAPIN) and ERBIN, in epithelial cells. Oncogene 21, 7042‐7049 (2002).
245. Kamei, T., et al. C‐Cbl protein in human cancer tissues is frequently tyrosine phosphorylated in a tumor‐specific manner. Int J Oncol 17, 335‐339 (2000).
246. Levkowitz, G., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c‐Cbl/Sli‐1. Mol Cell 4, 1029‐1040 (1999).
247. Hosaka, T., et al. Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c‐Cbl. Anticancer Res 27, 2253‐2263 (2007).
248. Ravid, T., Heidinger, J.M., Gee, P., Khan, E.M. & Goldkorn, T. c‐Cbl‐mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J Biol Chem 279, 37153‐37162 (2004).
249. Padron, D., et al. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down‐regulation but are efficiently internalized. Cancer Res 67, 7695‐7702 (2007).
250. Dowler, S., Montalvo, L., Cantrell, D., Morrice, N. & Alessi, D.R. Phosphoinositide 3‐kinase‐dependent phosphorylation of the dual adaptor for phosphotyrosine and 3‐phosphoinositides by the Src family of tyrosine kinase. Biochem J 349, 605‐610 (2000).
101
APPENDIX
Figure A.: Signaling pathway map of the EGFR pathway part of the curation effort of our lab as part of the NetPath project in mapping the entire pathway. Inset in red is a zoomed image of the pathway indicating the complexity of the pathway and the numerous cross talks with other adapter and signaling molecules
102
Table A List of peptides that were either unchanged (Unc) or activated (Act) on EGF treatment but were dephosphorylated on Erlotinib treatment. The phosphorylation sites are indicated by pY, pS or pT. L=light state, M=medium state and H=heavy state. Other post translational modifications are Oxidation (ox) and Acetylation (Ac)
Kinase 48 Adapter molecule 39 Transcription regulatory protein 28 Cytoskeletal associated protein 25 GTPase activating protein 24 Transport/cargo protein 21 Adhesion molecule 20 Cell junction protein 17 Transcription factor 16 Enzymes 13 Integral membrane protein 12 RNA binding protein 11 Structural protein 10 Calcium binding protein 10 Anchor protein 10 Membrane transport protein 8 ATPase 8 Ubiquitin proteasome system protein 7 Translation regulatory protein 5 Cell cycle control protein 5 Guanine nucleotide exchange factor 4 DNA binding protein 4 Chaperone 4 RNA helicase 3 Regulatory/other subunit 3 Protease inhibitor 3 Receptor tyrosine phosphatase 2 Motor protein 2 Unclassified 128 Others 9
Table B: List of molecules identified from each category classified based on molecular class